Axial Biotherapeutics Strengthens Senior Management Team with Appointment of Jeff Young as Chief Financial Officer

“Jeff is a highly experienced financial manager with a deep strategic understanding of the field. His addition to our management will greatly help us to continue building the strong financial foundations needed to support our progress in the clinic,” said David H. Donabedian, Ph.D., Co-founder and CEO of Axial Biotherapeutics. “Axial is advancing highly innovative programs for neurologic diseases and disorders, and we expect our drug candidates for both Parkinson’s disease and for Autism spectrum disorder to enter the clinic by the end of 2018.”

“Axial’s promising scientific basis, strong founders and leadership have generated a cutting-edge approach to discovering and developing novel therapeutics for neurological diseases and disorders by targeting the gastrointestinal tract,” said Jeffrey Young, Axial’s new CFO. “With multiple programs now advancing in and towards the clinic, I look forward to working with this exceptional team toward achieving our next set of milestones and establishing clinical proof of concept for Axial’s breakthrough approach.”

Mr. Young most recently served as CFO, Treasurer and Secretary at Juniper Pharmaceuticals, Inc., where he played an instrumental role in Juniper’s acquisition by Catalent. Prior to that, Mr. Young served as CFO and Treasurer of OvaScience, a global fertility company focused on new treatment options for women. Mr. Young was previously the CFO and Treasurer of Transmedics, a developer of medical devices for the maintenance and transport of organs between donors and recipients. Before that, he served as CFO and Treasurer at Lantheus Medical Imaging, where he led and managed multiple public debt offerings. Mr. Young began his career holding various positions of increasing responsibility in finance at Critical Therapeutics, PerkinElmer, Inc. and PriceWaterhouseCoopers LLP. Mr. Young holds a Bachelor of Science in Business Administration from Georgetown University.

Dr. Dennis Yamashita is a highly experienced and accomplished drug developer and medicinal chemist with extensive leadership experience at GSK and in biotech. Prior to joining Axial, Dr. Yamashita held various leadership roles at GSK, ORIC, and Trevena. Most recently, he was VP Drug Discovery of ORIC (Overcoming Resistance in Cancer) and was formerly VP Chemistry at Trevena. At GSK, Dr. Yamashita was Executive Director in Discovery Partnerships with Academia in Cambridge, MA and was also Director of Medicinal Chemistry in Microbial, Musculoskeletal, and Proliferative Diseases Center of Excellence Drug Discovery in Philadelphia, PA. Dr. Yamashita holds a Bachelor of Science in Chemistry from MIT and a Ph.D. in Organic Chemistry from Yale University.

About Axial Biotherapeutics:
Axial Biotherapeutics is a leading biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. www.axialbiotherapeutics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005088/en/